Clinical meaning
Dengue fever is caused by the dengue virus (DENV), a single-stranded positive-sense RNA virus belonging to the Flaviviridae family. Four distinct serotypes exist (DENV-1 through DENV-4), and infection with one serotype provides lifelong immunity to that specific serotype but only temporary cross-protection against the others. This is critically important because secondary infection with a different serotype carries a significantly higher risk of severe dengue through a phenomenon called antibody-dependent enhancement (ADE). In ADE, non-neutralizing antibodies from the first infection bind to the new dengue serotype and facilitate viral entry into Fc-receptor-bearing cells (monocytes and macrophages), paradoxically increasing viral replication rather than neutralizing the virus. The primary vector for dengue transmission is the Aedes aegypti mosquito, with Aedes albopictus serving as a secondary vector. These mosquitoes are daytime feeders, with peak biting activity occurring during early morning and late afternoon hours. Aedes aegypti is a peridomestic species that breeds in small collections of standing water including flower pots, discarded tires, rain barrels, and water storage containers. The mosquito acquires the virus by feeding on an infected human during the viremic phase (typically 2 days before symptom onset through 5-7 days after) and becomes infectious after an extrinsic incubation period of 8-12 days, remaining infectious for the remainder of its lifespan. After the infected mosquito bites a susceptible human, the virus replicates in local dendritic cells and macrophages at the site of inoculation, then disseminates through the lymphatic system and bloodstream. The incubation period in humans is 4-10 days. Dengue pathogenesis involves complex interactions between the virus and the host immune system. Infected dendritic cells and macrophages release a cascade of pro-inflammatory cytokines and chemokines, including tumor necrosis factor alpha (TNF-alpha), interleukins (IL-6, IL-8, IL-10), and interferon gamma. This cytokine storm causes increased vascular permeability, the hallmark of severe dengue. The endothelial glycocalyx layer is disrupted, plasma leaks from the intravascular space into the interstitial compartment and serous cavities (pleural effusion, ascites), and intravascular volume decreases. Thrombocytopenia in dengue results from multiple mechanisms: direct viral infection of bone marrow precursor cells suppresses megakaryopoiesis, circulating immune complexes cause peripheral platelet destruction, and activated platelets are consumed in damaged endothelium. The combination of increased vascular permeability, plasma leakage, thrombocytopenia, and coagulopathy creates the conditions for dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The World Health Organization classifies dengue into dengue without warning signs, dengue with warning signs, and severe dengue. Warning signs typically appear during defervescence (when fever breaks, usually days 3-7) and include persistent vomiting, severe abdominal pain, mucosal bleeding, lethargy or restlessness, hepatomegaly, and a rising hematocrit concurrent with a rapidly falling platelet count. The critical phase during defervescence is when plasma leakage peaks and patients are at highest risk for cardiovascular collapse. Severe dengue is defined by severe plasma leakage leading to shock or respiratory distress from fluid accumulation, severe bleeding, or severe organ impairment (liver transaminases above 1000 IU/L, encephalitis, or myocarditis). The tourniquet test (inflating a blood pressure cuff midway between systolic and diastolic for 5 minutes and counting petechiae) is a bedside screening tool; 20 or more petechiae in a 2.5 cm square area is considered positive and suggests capillary fragility associated with dengue. The practical nurse plays a critical role in serial platelet monitoring, fluid balance assessment, recognizing warning signs, and supporting hemodynamic stability through careful fluid management during the critical phase.